Live Search
 
   



 

Annual Meeting of the GTA

May 3-4, 2018
John M. Clayton Hall Conference Center
University of Delaware
Newark, DE

Speakers Presentations

Keynote Speaker:

Yan Zhang
University of Michigan

CRISPR Overview and Practical Applications

Back to Top

Symposium I: CRISPR, a powerful new technology: Applications and regulatory issues

Eric Kmiec
Helen F. Graham Cancer Center

CRISPR-Directed Gene Editing in vitro; a Novel System for the Identification of Regulatory and Genotoxic Factors in a Cell-Free Environment


Marco Jost
UCSF

CRISPRi/a-Based Chemical-Genetic Screens for Small Molecule Target Identification

 

 

Sandhya Sanduja
US FDA

Regulatory Considerations for CRISPR/Cas-based Gene Edited Products: An FDA Perspective

Back to Top

Symposium II: Case Studies/Key Problems in Genetic Toxicology

John Nicolette
Abbvie

Case Study: I Can See Clearly Now (Genetox is Done!)

 

Zhanna Sobol
Pfizer Worldwide Research and Development

Sex, Drugs and GeneTox

 

Krista Dobo
Pfizer Worldwide Research and Development

Risk Assessment of Two Mutagenic Diboron Reagents

 

Richard Williams
Lhasa

Are All Ames Strains in the OECD Mutagenicity Test Guideline 471 Useful and Necessary? An Analysis of Large Mutagenicity Data Sets for the IWGT

Back to Top

Symposium III: Case Studies Focus Topic: Aryl Boronic Acids in Pharmaceutical Development

Joel Bercu
Gilead

Arylboronic Acids: Introduction and Review of Bacterial Mutagenicity



Michelle Kenyon / Vijay Reddy
Pfizer Worldwide Research and Development / Merck

Genotixicity of Aryl Boronic Acids In Vitro in Mammalian Cells

Evaluation of DNA Adduct Formation with Boronic Acid Derivatives by LC/MS



Melisa Masuda-Herrera

Gilead

In Vivo Genotoxicity of Arylboronic Acids: To Be or Not To Be

Back to Top

dotted line

Symposium IV: IWGT 2017 Update

Rodger Curren
Institute for In Vitro Sciences

Use of 3D Tissues in Genotoxicity Testing

 

Errol Zeiger
Errol Zeiger Consulting

Revisiting the Bacterial Mutagenicity (Ames) Test

 

Maik Schuler
Pfizer Worldwide Research and Development

Risk of AneugensWorkgroup



Bhaskar Gollapudi

Exponent

In Vitro Mammalian Cell Gene Mutation (MCM) Assays Working Group



Dan Levy

US FDA

In vivo Strategies Working Group

Back to Top

dotted liine

Symposium V: Tools and Approaches for Clinical Biomonitoring of Genomic Damage

Zach Nagel
Harvard University

Comprehensive Analysis of DNA Repair Capacity in Human Leukocyte Subtypes

 

Qingyi Wei
Duke University

A Novel Variant in DNA Repair Gene GTF2H4 Associated with Lung Cancer Risk

 

Robert Sobol
University of South Alabama Mitchell Cancer Institute

Advanced Tools for DNA Repair and DNA Damage Analysis

Back to Top

dotted line

Symposium VI: Mechanisms of Actions

Chris Corton
US EPA

Using Gene Expression Biomarkers to Identify Potential Carcinogens



Liz Rubitski

Pfizer Worldwide Research and Development

The Role of Cellular Imaging in the Mode of Action Assessment of
Clastogens and Aneugens



Nikolai Chepelev

Health Canada

Genotoxic Mode of Action of Acrylamide

Back to Top

dotted line

               Home     |     Who We Are     |     Board of Directors     |     Past Scientific Meetings     |     BOD Meeting Minutes     |     Contact
Who We Are 2018 Scientific Meeting Members Only Membership Application/Renewal Corporate Sponsorship GTA Home Page GTA Home Page Email